Pyrimethamine is a medication used for protozoan infections. It is commonly used as an antimalarial drug (for both treatment and prevention of malaria), and to treat Toxoplasma gondii infections, particularly when combined with the sulfonamide antibiotic sulfadiazine when treating HIV-positive individuals. Pyrimethamine is typically given with a sulfonamide and folinic acid due to its resistance against many Plasmodium species. Pyrimethamine has also been found to limit the expression of the superoxide dismutase 1 gene, a protein involved in amyotrophic lateral sclerosis.
MARKET DYNAMICS
The pyrimethamine market is driving due to the rising number of HIV positive patients worldwide and immunosuppressed individual at a risk of infections. However, factors such as pricing issues in some countries and resistance developing against the drugs may hamper the growth of market during the forecast period. Moreover, mergers and acquisitions by the manufacturing companies would also the boost the demand and supply for the pyrimethamine medication in the pyrimethamine treatment market.
MARKET SCOPE
The "Pyrimethamine Market Analysis to 2028" is a specialized and in-depth study of the pharmaceutical industry with a special focus on the global market trend analysis. The report aims to provide an overview of pyrimethamine market with detailed market segmentation by of product, technology, application and end user. The pyrimethamine market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in pyrimethamine market and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The pyrimethamine market is segmented on the basis of type, and application. Based on type, the market is segmented as injectables, capsules and tablets. On the basis of application, the market is categorized as hospital, clinic, laboratory and others.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the pyrimethamine market based on various segments. It also provides market size and forecast estimates from year 2020 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The pyrimethamine market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting pyrimethamine market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the pyrimethamine market in these regions.
MARKET PLAYERS
The report covers key developments in the pyrimethamine market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from pyrimethamine market are anticipated to have lucrative growth opportunities in the future with the rising demand for pyrimethamine in the global market. Below mentioned is the list of few companies engaged in the pyrimethamine market.
The report also includes the profiles of key players in pyrimethamine market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
- Evaluate
- GlaxoSmithKline plc
- Impax Laboratories, Inc.
- NCBO BioPortal
- Pfizer, Inc.
- PRN Pharmacal
- SUDA Pharmaceuticals
- Taj Accura Pharmaceuticals
- TargetMol
- Turing Pharmaceuticals
The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.